Roche Announces NMPA Approval of Actemra® (Tocilizumab) Subcutaneous Monotherapy in China for Rheumatoid Arthritis

According to Roche, on August 22, China's National Medical Products Administration (NMPA) officially approved Actemra® (generic name: Tocilizumab Injection (Subcutaneous Injection)) as a monotherapy for the treatment of adult patients with moderate to severe active rheumatoid arthritis who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs), and who have had an inadequate response or are intolerant to methotrexate (MTX).